Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Symptoms and signs of indication of lymphocytic colitis~Exclusion Criteria:~* Infectious diarrhoea,~* Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopic-histological findings Celiac disease~* Pregnancy or breast-feeding,~* Participation in an other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Budesonide
- B (Type: EXPERIMENTAL): Mesalazine
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).